Live Breaking News & Updates on Clinical trial program

Stay informed with the latest breaking news from Clinical trial program on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Clinical trial program and stay connected to the pulse of your community

Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn's Disease -March 28, 2024 at 04:02 pm EDT

Bristol Myers Squibb today announced an update following the initial analysis of results from the first of two induction studies in the Phase 3 YELLOWSTONE clinical trial program evaluating Zeposia ...

Roland-chen , Bristol-myers-squibb , Facebook , Twitter , Exchange-commission , Clinical-trial-program , Youtube , Instagram , Linkedin , Bristol-myers , Disease-activity-index , Simple-endoscopic-score

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q4 2023 Earnings Call Transcript

Operator: Good morning ladies and gentlemen and welcome to the Amicus Therapeutics' Full Year 2023 Financial Results Conference Call and Webcast.

United-states , Germany , United-kingdom , San-diego , California , Japan , Austria , Jeff-gatseli , Salveen-richter , Asia-pacific , Simon-harford , Bradley-campbell

Zealand Pharma submits New Drug Application to the US FDA for glepaglutide in short bowel syndrome

Press release – No. 18 / 2023 Zealand Pharma submits New Drug Application to the US FDA for glepaglutide in short bowel syndrome Copenhagen, Denmark, December 22, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for glepaglutide, a long-acting GLP-2 analog, for th

Copenhagen , Køavn- , Denmark , Zealand-pharma , David-kendall , Anna-krassowska , Drug-administration , Clinical-trial-program , Investor-relations-corporate-communications , New-drug-application , Chief-medical-officer , Investor-relations

Merck Provides Update on Phase III Results for Evobrutinib in Relapsing Multiple Sclerosis

Merck Provides Update on Phase III Results for Evobrutinib in Relapsing Multiple Sclerosis
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

United-states , Canada , Clinical-trial-program , Serono , Global-head-of-research-development , Product-service , Provides-update , Relapsing-multiple , Danny-bar-zohar , Global-head , Chief-medical-officer

Merck KGaA, Darmstadt, Germany Provides Update on Phase III Results for Evobrutinib in Relapsing Multiple Sclerosis

Merck KGaA, Darmstadt, Germany Provides Update on Phase III Results for Evobrutinib in Relapsing Multiple Sclerosis
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Germany , United-states , Canada , Stefan-klotter , Serono , Global-head-of-research-development , Merck-kga , Merck-kgaa , Clinical-trial-program , Danny-bar-zohar , Global-head , Research-development

Merck Provides Update on Phase III Results for Evobrutinib in Relapsing Multiple Sclerosis

Merck Provides Update on Phase III Results for Evobrutinib in Relapsing Multiple Sclerosis
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United-states , United-kingdom , Canada , Stefan-klotter , Clinical-trial-program , Global-head-of-research-development , Serono , Danny-bar-zohar , Global-head , Research-development , Chief-medical-officer , Lassen-sie

Merck KGaA, Darmstadt, Germany Provides Update on Phase III Results for Evobrutinib in Relapsing Multiple Sclerosis

Merck KGaA, Darmstadt, Germany Provides Update on Phase III Results for Evobrutinib in Relapsing Multiple Sclerosis
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Germany , United-states , Canada , Merck-kgaa , Global-head-of-research-development , Clinical-trial-program , Merck-kga , Serono , Danny-bar-zohar , Global-head , Chief-medical-officer

FDA Approves Lilly's Omvoh™ (mirikizumab-mrkz), A First-in-Class Treatment for Adults with Moderately to Severely Active Ulcerative Colitis

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh™ (mirikizumab-mrkz)...

Japan , United-states , Bruce-sands , Rachel-sorvig , Burrillb-crohn , Patrik-jonsson , Prnewswire-eli-lilly , Joe-fletcher , Eli-lilly , Drug-administration , Lilly-answers-center , Exchange-commission

FDA Approves Lilly's Omvoh™ (mirikizumab-mrkz), A First-in-Class Treatment for Adults with Moderately to Severely Active Ulcerative Colitis

FDA Approves Lilly's Omvoh™ (mirikizumab-mrkz), A First-in-Class Treatment for Adults with Moderately to Severely Active Ulcerative Colitis
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-states , Japan , Prnewswire-eli-lilly , Eli-lilly , Joe-fletcher , Bruce-sands , Burrillb-crohn , Patrik-jonsson , Rachel-sorvig , Twitter , Lilly-answers-center , Exchange-commission

TCT23 Late-breakers: Full Schedule Announced

Late-breaking trials will be presented during the main sessions and highlighted during press conferences scheduled for Oct. 24, 25 and 26

United-states , San-francisco , California , American , Suzannev-arnold , Davide-kandzari , Robertl-smith , Davidh-adams , Amitn-vora , Susheelk-kodali , Joanna-chikwe , Suzannej-baron